Eduardo M CastaÃ±o

List of Publications by Year
in descending order

41 papers	3,922 citations	201674 27 h-index	315739 38 g-index
41 all docs	41 docs citations	41 times ranked	4610 citing authors

#	Article	IF	Citations
1	Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations. Neurochemistry International, 2013, 62, 145-156.	3.8	45
2	Transcriptional Regulation of Insulin-degrading Enzyme Modulates Mitochondrial Amyloid Î² (AÎ²) Peptide Catabolism and Functionality. Journal of Biological Chemistry, 2013, 288, 12920-12931.	3.4	31
3	Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: Implications for cellular AÎ² metabolism. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 227-235.	4.1	30
4	Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1508-1514.	3.8	48
5	Alzheimer's Disease and Non-Demented High Pathology Control Nonagenarians: Comparing and Contrasting the Biochemistry of Cognitively Successful Aging. PLoS ONE, 2011, 6, e27291.	2.5	65
6	The biochemical aftermath of anti-amyloid immunotherapy. Molecular Neurodegeneration, 2010, 5, 39.	10.8	38
7	Insulin-Degrading Enzyme Sorting in Exosomes: A Secretory Pathway for a Key Brain Amyloid-Î² Degrading Protease. Journal of Alzheimer's Disease, 2010, 19, 79-95.	2.6	126
8	Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects. Current Alzheimer Research, 2009, 6, 399-406.	1.4	32
9	Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 18-29.	0.8	322
10	Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Molecular Neurodegeneration, 2008, 3, 20.	10.8	55
11	Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to AÎ² and insulin degradation. Molecular Neurodegeneration, 2008, 3, 22.	10.8	40
12	Tg-SwDI Transgenic Mice Exhibit Novel Alterations in AÎ²PP Processing, AÎ² Degradation, and Resilient Amyloid Angiopathy. American Journal of Pathology, 2008, 173, 483-493.	3.8	30
13	The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme. Prion, 2008, 2, 51-56.	1.8	26
14	The Catalytic Domain of Insulin-degrading Enzyme Forms a Denaturant-resistant Complex with Amyloid Î² Peptide. Journal of Biological Chemistry, 2008, 283, 17039-17048.	3.4	34
15	Amyloid-Î² Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients. American Journal of Pathology, 2006, 169, 1048-1063.	3.8	196
16	Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology. Journal of Neuropathology and Experimental Neurology, 2006, 65, 976-987.	1.7	67
17	Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurological Research, 2006, 28, 155-163.	1.3	188
18	Amyloid Î² Degradation: A Challenging Task for Brain Peptidases. , 2005, 38, 129-145.		18

#	Article	IF	Citations
19	Altered APP Processing in PDAPP (Val717 â†' Phe) Transgenic Mice Yields Extended-Length AÎ² Peptidesâ€. Biochemistry, 2005, 44, 13807-13819.	2.5	28
20	Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia. Biochemical and Biophysical Research Communications, 2005, 332, 808-816.	2.1	27
21	Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurological Research, 2004, 26, 525-539.	1.3	154
22	Insulin-degrading Enzyme in Brain Microvessels. Journal of Biological Chemistry, 2004, 279, 56004-56013.	3.4	62
23	Differential Degradation of Amyloid Î² Genetic Variants Associated with Hereditary Dementia or Stroke by Insulin-degrading Enzyme. Journal of Biological Chemistry, 2003, 278, 23221-23226.	3.4	75
24	Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration. Neuroscience Letters, 2002, 326, 9-12.	2.1	19
25	The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses. Neurochemical Research, 2002, 27, 1387-1399.	3.3	23
26	Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochemical Research, 2000, 25, 247-255.	3.3	220
27	Differential accumulation of soluble amyloid Î² peptides 1-40 and 1-42 in human monocytic and neuroblastoma cell lines. Cell and Tissue Research, 1999, 298, 225-232.	2.9	11
28	Internalization and resistance to degradation of Alzheimer's AÎ²1â€“42 at nanomolar concentrations in THP-1 human monocytic cell line. Neuroscience Letters, 1999, 262, 5-8.	2.1	17
29	Î²-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nature Medicine, 1998, 4, 822-826.	30.7	831
30	Immunoglobulin lambda light chains are the precursors of ureteral localized amyloidosis: a micromethod for extraction of amyloid. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 253-258.	3.0	14
31	The conformation of Alzheimer's Î² peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochemical Journal, 1996, 314, 701-707.	3.7	120
32	The length of Amyloid-Î² in Hereditary Cerebral Hemorrhage with Amyloidosis, Dutch Type. Journal of Biological Chemistry, 1996, 271, 32185-32191.	3.4	86
33	Apolipoprotein E and Amyloidogenesis. Novartis Foundation Symposium, 1996, 199, 132-145.	1.1	6
34	The Î±-Helical to Î²-Strand Transition in the Amino-terminal Fragment of the Amyloid Î²-Peptide Modulates Amyloid Formation. Journal of Biological Chemistry, 1995, 270, 3063-3067.	3.4	298
35	Fibrillogenesis of synthetic amyloid-Î² peptides is dependent on their initial secondary structure. Neuroscience Letters, 1995, 200, 105-108.	2.1	144
36	Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, Gelsolin and AA amyloids. FEBS Letters, 1995, 371, 110-114.	2.8	50

#	Article	IF	Citations
37	Alzheimer's Disease from the Perspective of the Systemic and Localized Forms of Amyloidosis. Brain Pathology, 1991, 1, 263-271.	4.1	23
38	Biology of Disease. , 1989, , 25-35.		0
39	Different processing of Alzheimer's Î²-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochemical and Biophysical Research Communications, 1988, 151, 1150-1155.	2.1	84
40	Human Amyloidosis and In Vitro Formation of Alzheimer Amyloid Fibrils. Advances in Behavioral Biology, 1987, , 33-44.	0.2	0
41	In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to alzheimer's disease Î²-protein. Biochemical and Biophysical Research Communications, 1986, 141, 782-789.	2.1	239